EGFR and neoplasm: Due to the invasive phenotype and high angiogenic activity of cancer cells, the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) are commonly overexpressed in tumor tissues and, therefore, are frequent targets for cancer therapies.